


IN THE CLAIMS

Please cancel Claims 1-22.

Please enter new Claims 23-68 as they appear below.

23. (New) A method of treating a neovasucular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of EM-138,



or a hydrolysis product or a metabolite thereof.


24. (New) The method of Claim 23, wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.
25. (New) The method of Claim 24, wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.
26. (New) The method of Claim 25, wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.
27. (New) The method of Claim 23, wherein the compound is administered in the form of a tablet or capsule.

28. (New) The method of Claim 23, wherein the compound is administered in the form of a lozenge, a capsule, a cachet, a tablet, a solution, a suspension, an emulsion, a bolus, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tampon or a pessary.
29. (New) The method of Claim 23, wherein the administration is oral, parenteral, transdermal or topical.
30. (New) The method of Claim 23, wherein the administration is buccal, rectal, vaginal or nasal.
31. (New) The method of Claim 23, wherein the eye condition is diabetic retinopathy.
32. (New) The method of Claim 23, wherein the eye condition is retinopathy of prematurity.
33. (New) The method of Claim 23, wherein the eye condition is corneal graft rejection.
34. (New) The method of Claim 23, wherein the eye condition is neovascular glaucoma.
35. (New) The method of Claim 23, wherein the eye condition is retrolental fibroplasias.
36. (New) The method of Claim 23, wherein the eye condition is epidemic keratoconjunctivitis.
37. (New) The method of Claim 23, wherein the eye condition is Vitamin A deficiency.
38. (New) The method of Claim 23, wherein the eye condition is contact lens overwear.
39. (New) The method of Claim 23, wherein the eye condition is atopic keratitis.

10035037-121901
A3

40. (New) The method of Claim 23, wherein the eye condition is superior limbic keratitis.
41. (New) The method of Claim 23, wherein the eye condition is pterygium keratitis sicca.
42. (New) The method of Claim 23, wherein the eye condition is myopia.
43. (New) The method of Claim 23, wherein the eye condition is Terrien's marginal degeneration.
44. (New) The method of Claim 23, wherein the eye condition is marginal keratolysis.
45. (New) The method of Claim 23, wherein the eye condition is radial keratotomy.
46. (New) The method of Claim 23, wherein the eye condition is macular degeneration.
47. (New) The method of Claim 23, wherein the eye condition is post-laser complications.
48. (New) The method of Claim 23, wherein the eye condition is chronic retinal detachment.
49. (New) The method of Claim 23, wherein the eye condition is optic pits.
50. (New) The method of Claim 23, wherein the eye condition is a hyperviscosity syndrome.
51. (New) The method of Claim 23, wherein the eye condition is chronic uveitis
52. (New) The method of Claim 23, wherein the eye condition is chronic vitritis.
53. (New) The method of Claim 23, wherein the eye condition is ocular neovascular disease.

54. (New) The method of Claim 23, wherein the eye condition is age-related macular degeneration.
55. (New) The method of Claim 23, wherein the eye condition is presumed ocular histoplasmosis.
56. (New) The method of Claim 23, wherein the eye condition is an infection causing retinitis or choroiditis.
57. (New) The method of Claim 23, wherein the eye condition is proliferative vitreoretinopathy.
58. (New) The method of Claim 23, wherein the eye condition is scleritis.
59. (New) The method of Claim 23, wherein the eye condition is Eales' disease.
60. (New) The method of Claim 23, wherein the eye condition is Best's disease.
61. (New) The method of Claim 23, wherein the eye condition is trachoma.
62. (New) A method of treating a neovasacular eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal a pharmaceutically effective amount of a composition comprising EM-138,



a hydrolysis product thereof or a metabolite thereof.

63. (New) The method of Claim 62, wherein the effective amount is between approximately 0.1 and approximately 300 mg/kg/day.

64. (New) The method of Claim 62, wherein the effective amount is between approximately 0.5 and approximately 50 mg/kg/day.

65. (New) The method of Claim 62, wherein the effective amount is between approximately 1 and approximately 10 mg/kg/day.

66. (New) The method of Claim 62, wherein the composition is in the form of a tablet, capsule, a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, a granule, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tampon, or a pessary.

67. (New) The method of Claim 62, further comprising an additive selected from an anti-oxidant, a buffer, a bacteriostat, a solute which renders the composition isotonic with the blood of the human or the animal, a suspending agent, a thickening agent, a flavoring agent, a gelatin, glycerine, a diluent, or any combination thereof.

68. (New) The composition of Claim 62, further comprising a biodegradable polymer.

10026037-121001
F06T21-2509200F